Aug. 10 at 12:24 PM
$PHIO @Go_Stock_yourself The ideas that I have advanced are that while
$PHIO is a good company, with good management, a good board, good staff and an excellent drug prospects it does have some downsides. Research is still at an early stage and although the press releases from stage one trials looked promising, we still haven’t seen the statistical analysis and write up of the trial. Financing, has always been a problem for
$PHIO – the novel aspects of its drug are a doubled edged sword- and as the excellent Sidoti report makes clear there will need to be more financing rounds and thus more dilution which is likely to have an adverse effect on price.
Thus, I remain of the opinion that
$PHIO is 20 to 25 percent overvalued and thus remain bearish in the short to medium run although I am bullish in the long run.
If you have a different view I encourage you to write several sentences setting our your argument. That way we can have an exchange of ideas the platform seeks to promote.
